Annual Retained Earnings
$359.87 M
+$269.32 M+297.43%
December 31, 2024
Summary
- As of February 26, 2025, HALO annual retained earnings is $359.87 million, with the most recent change of +$269.32 million (+297.43%) on December 31, 2024.
- During the last 3 years, HALO annual retained earnings has risen by +$418.78 million (+710.86%).
- HALO annual retained earnings is now at all-time high.
Performance
HALO Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Retained Earnings
$359.87 M
-$37.76 M-9.50%
December 31, 2024
Summary
- As of February 26, 2025, HALO quarterly retained earnings is $359.87 million, with the most recent change of -$37.76 million (-9.50%) on December 31, 2024.
- Over the past year, HALO quarterly retained earnings has increased by +$269.32 million (+297.43%).
- HALO quarterly retained earnings is now -9.50% below its all-time high of $397.63 million, reached on September 30, 2024.
Performance
HALO Quarterly Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Retained Earnings Formula
Retained Earnings = Retained Earnings (start of the period) + Net Income − Dividends Paid
HALO Retained Earnings Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +297.4% | +297.4% |
| 3 y3 years | +710.9% | +61.9% |
| 5 y5 years | +159.6% | +61.9% |
HALO Retained Earnings Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +710.9% | -9.5% | +710.9% |
| 5 y | 5-year | at high | +159.6% | -9.5% | +159.0% |
| alltime | all time | at high | +159.6% | -9.5% | +155.4% |
Halozyme Therapeutics Retained Earnings History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $359.87 M(+297.4%) | $359.87 M(-9.5%) |
| Sep 2024 | - | $397.63 M(+52.6%) |
| Jun 2024 | - | $260.62 M(+55.7%) |
| Mar 2024 | - | $167.37 M(+84.8%) |
| Dec 2023 | $90.55 M(-36.8%) | $90.55 M(-59.3%) |
| Sep 2023 | - | $222.28 M(+58.3%) |
| Jun 2023 | - | $140.45 M(+113.8%) |
| Mar 2023 | - | $65.69 M(-54.1%) |
| Dec 2022 | $143.22 M(-343.1%) | $143.22 M(+67.5%) |
| Sep 2022 | - | $85.52 M(+258.1%) |
| Jun 2022 | - | $23.88 M(+1896.7%) |
| Mar 2022 | - | $1.20 M(-102.0%) |
| Dec 2021 | -$58.91 M(-87.6%) | -$58.91 M(-53.1%) |
| Sep 2021 | - | -$125.68 M(-63.3%) |
| Jun 2021 | - | -$342.27 M(-21.1%) |
| Mar 2021 | - | -$433.73 M(-8.6%) |
| Dec 2020 | -$474.59 M(-21.4%) | -$474.59 M(-13.4%) |
| Sep 2020 | - | -$547.76 M(-6.2%) |
| Jun 2020 | - | -$583.96 M(-4.2%) |
| Mar 2020 | - | -$609.78 M(+1.0%) |
| Dec 2019 | -$603.68 M(+13.6%) | -$603.68 M(+6.0%) |
| Sep 2019 | - | -$569.28 M(+4.6%) |
| Jun 2019 | - | -$544.27 M(+2.8%) |
| Mar 2019 | - | -$529.64 M(-0.3%) |
| Dec 2018 | -$531.44 M(+1.7%) | -$531.44 M(+0.4%) |
| Sep 2018 | - | -$529.31 M(+5.6%) |
| Jun 2018 | - | -$501.46 M(+4.8%) |
| Mar 2018 | - | -$478.57 M(-8.4%) |
| Dec 2017 | -$522.37 M(-10.8%) | -$522.37 M(-19.2%) |
| Sep 2017 | - | -$646.25 M(-0.4%) |
| Jun 2017 | - | -$649.00 M(+5.0%) |
| Mar 2017 | - | -$618.24 M(+5.6%) |
| Dec 2016 | -$585.34 M(+21.3%) | -$585.34 M(+4.9%) |
| Sep 2016 | - | -$557.96 M(+5.5%) |
| Jun 2016 | - | -$529.01 M(+5.4%) |
| Mar 2016 | - | -$502.13 M(+4.0%) |
| Dec 2015 | -$482.66 M(+7.2%) | -$482.66 M(-0.9%) |
| Sep 2015 | - | -$486.98 M(+5.3%) |
| Jun 2015 | - | -$462.52 M(-0.6%) |
| Mar 2015 | - | -$465.54 M(+3.4%) |
| Dec 2014 | -$450.43 M(+17.9%) | -$450.43 M(+1.2%) |
| Sep 2014 | - | -$445.15 M(+4.8%) |
| Jun 2014 | - | -$424.87 M(+4.0%) |
| Mar 2014 | - | -$408.60 M(+6.9%) |
| Dec 2013 | -$382.05 M | -$382.05 M(+6.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2013 | - | -$360.07 M(+5.7%) |
| Jun 2013 | - | -$340.77 M(+7.2%) |
| Mar 2013 | - | -$317.86 M(+6.5%) |
| Dec 2012 | -$298.57 M(+21.9%) | -$298.57 M(+1.5%) |
| Sep 2012 | - | -$294.17 M(+7.3%) |
| Jun 2012 | - | -$274.16 M(+5.4%) |
| Mar 2012 | - | -$260.14 M(+6.2%) |
| Dec 2011 | -$245.02 M(+8.8%) | -$245.02 M(+8.1%) |
| Sep 2011 | - | -$226.61 M(-2.2%) |
| Jun 2011 | - | -$231.77 M(-1.3%) |
| Mar 2011 | - | -$234.89 M(+4.3%) |
| Dec 2010 | -$225.25 M(+31.0%) | -$225.25 M(+8.1%) |
| Sep 2010 | - | -$208.36 M(+6.3%) |
| Jun 2010 | - | -$195.95 M(+6.6%) |
| Mar 2010 | - | -$183.80 M(+6.9%) |
| Dec 2009 | -$172.01 M(+51.4%) | -$172.01 M(+7.9%) |
| Sep 2009 | - | -$159.35 M(+9.6%) |
| Jun 2009 | - | -$145.44 M(+13.3%) |
| Mar 2009 | - | -$128.38 M(+13.0%) |
| Dec 2008 | -$113.65 M(+74.9%) | -$113.65 M(+17.4%) |
| Sep 2008 | - | -$96.82 M(+12.6%) |
| Jun 2008 | - | -$85.95 M(+14.7%) |
| Mar 2008 | - | -$74.95 M(+15.3%) |
| Dec 2007 | -$65.00 M(+58.1%) | -$65.00 M(+15.5%) |
| Sep 2007 | - | -$56.29 M(+14.3%) |
| Jun 2007 | - | -$49.26 M(+10.8%) |
| Mar 2007 | - | -$44.46 M(+8.2%) |
| Dec 2006 | -$41.10 M(+56.0%) | -$41.10 M(+11.9%) |
| Sep 2006 | - | -$36.72 M(+11.0%) |
| Jun 2006 | - | -$33.07 M(+10.8%) |
| Mar 2006 | - | -$29.84 M(+13.2%) |
| Dec 2005 | -$26.35 M(+101.6%) | -$26.35 M(+15.4%) |
| Sep 2005 | - | -$22.83 M(+19.3%) |
| Jun 2005 | - | -$19.13 M(+17.6%) |
| Mar 2005 | - | -$16.27 M(+24.4%) |
| Dec 2004 | -$13.07 M(>+9900.0%) | -$13.07 M(+23.4%) |
| Sep 2004 | - | -$10.59 M(+44.3%) |
| Jun 2004 | - | -$7.34 M(+39.4%) |
| Mar 2004 | - | -$5.26 M(+3946.8%) |
| Sep 2003 | - | -$130.10 K(+7.9%) |
| Jun 2003 | - | -$120.60 K(+5.1%) |
| Mar 2003 | - | -$114.80 K(+94.6%) |
| Sep 2002 | - | -$59.00 K(+27.2%) |
| Jun 2002 | - | -$46.40 K(+53.1%) |
| Mar 2002 | - | -$30.30 K |
| Dec 2001 | -$39.70 K | - |
FAQ
- What is Halozyme Therapeutics annual retained earnings?
- What is the all time high annual retained earnings for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual retained earnings year-on-year change?
- What is Halozyme Therapeutics quarterly retained earnings?
- What is the all time high quarterly retained earnings for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly retained earnings year-on-year change?
What is Halozyme Therapeutics annual retained earnings?
The current annual retained earnings of HALO is $359.87 M
What is the all time high annual retained earnings for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual retained earnings is $359.87 M
What is Halozyme Therapeutics annual retained earnings year-on-year change?
Over the past year, HALO annual retained earnings has changed by +$269.32 M (+297.43%)
What is Halozyme Therapeutics quarterly retained earnings?
The current quarterly retained earnings of HALO is $359.87 M
What is the all time high quarterly retained earnings for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly retained earnings is $397.63 M
What is Halozyme Therapeutics quarterly retained earnings year-on-year change?
Over the past year, HALO quarterly retained earnings has changed by +$269.32 M (+297.43%)